MRI 鉴别子宫肉瘤与肌瘤的操作要点解读
子宫肉瘤(通常为平滑肌肉瘤)在拟诊肌瘤手术的女性中检出风险可达 1/770。增强 MRI 联合 DWI 及 ADC 检测子宫平滑肌肉瘤的准确率为 88%–94.6%。作者对 Radiology 2023 版子宫肿块 MRI 风险评估共识中的算法进行补充细化,以提高临床实用性。
要点
- 增强 MRI 联合 DWI/ADC 检测子宫平滑肌肉瘤准确率为 88%–94.6%。
- 对拟手术或微创治疗的子宫肿块,阅片时应主动评估肉瘤风险。
- 可参考 Radiology 2023 子宫肿块 MRI 风险评估共识算法,并结合补充征象判断。
核心结论
- 增强 MRI 联合 DWI 及 ADC 对检测子宫平滑肌肉瘤具有高准确率(88%–94.6%)。
- 放射科医师可在子宫肉瘤风险评估与疾病管理中发挥重要协作作用。
- Radiology 2023 共识算法已获初步验证,作者提出的补充征象有助于优化临床应用。
研究设计与样本
- 作者依据 Radiology 2023 年子宫肿块 MRI 风险评估共识声明,结合自身经验提出操作要点与征象补充。
诊断标准与关键数值
- 增强 MRI 联合 DWI 和 ADC 检测子宫平滑肌肉瘤的准确率为 88%–94.6%。
- 采用 Radiology 2023 MRI Evaluation of Uterine Masses for Risk of Leiomyosarcoma 共识声明中的算法进行风险分层。
临床应用与阅片要点
- 对拟行手术或微创治疗的子宫肿块患者,阅片时应将肉瘤风险评估纳入常规报告思路。
- 应用共识算法并结合作者补充的征象细节,可减少对未预料子宫平滑肌肉瘤的漏诊。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The prevalence of uterine sarcoma, typically leiomyosarcoma, is greater than previously believed, with current data indicating a risk as high as one in 770 women undergoing surgery for presumed leiomyomas (uterine fibroids). Presurgical detection of uterine sarcoma is an important clinical concern for gynecologists and gynecologic oncologists worldwide. Inadvertent minimally invasive treatment of unsuspected uterine leiomyosarcoma may delay definitive therapy or lead to disease dissemination. Contrast-enhanced MRI with diffusion-weighted imaging and apparent diffusion coefficient measurement provides high accuracy (88%-94.6%) in detecting uterine leiomyosarcoma, making radiologists valuable partners to gynecologists in risk assessment and disease management. The algorithm outlined in the Radiology 2023 MRI Evaluation of Uterine Masses for Risk of Leiomyosarcoma consensus statement has been preliminarily validated, and the authors present additional nuances to enhance its application in clinical practice.
引用
- Hindman, Tong, Huang, et al. How I Do It: Identifying Signs to Differentiate Uterine Sarcoma (Leiomyosarcoma) from Leiomyomas at MRI. Radiology. 2026. PMID: 42770820. doi:10.1148/radiol.252877
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。